

Nonclinical Development of PP1 Targeting Drug for Pulmonary Arterial Hypertension

NadianBio



CARDIOVASCULAR

Non-Clinical

| | |
|--------------------------|---|
| Product Type | Peptide product(36 mer) |
| Indication | 1st indication: Pulmonary Arterial Hypertension (MeSH term) 2nd indication: Pulmonary Hypertension (PH), Hypertension, Pulmonary (MeSH term) |
| Target | Protein Phosphatase 1(PP1) |
| MoA(Mechanism of Action) | Inhibition of PP1 holoenzyme → SERCA2A activation → Recovery of BMPR2 |
| Competitiveness | <ul style="list-style-type: none"> • A new concept of PH treatment by restoring the expression of BMPR2 to a normal level, inducing vasodilation and inhibiting vascular endothelial cell proliferation at the same time. • First-in-class drug for Group II and Group III PH patients. • Development of Dry Powder Inhalation formulation |
| Development Stage | Non-Clinical |
| Route of Administration | Intratracheal |